Unlabelled: We report a case of a 64-year-old man who, 44 days after starting treatment with prasugrel, presented with severe thrombocytopenia, anaemia, renal failure, and severe ADAMTS13 activity deficiency, along with a high titer of autoantibodies to this protease.

Learning Points: Drug-induced TTP is a rare condition and difficult to diagnose.Decreased activity of ADAMTS13, unusual in drug-induced TTP, was present in this case.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346962PMC
http://dx.doi.org/10.12890/2016_000446DOI Listing

Publication Analysis

Top Keywords

adamts13 activity
8
activity deficiency
8
drug-induced ttp
8
prasugrel acquired
4
acquired thrombotic
4
thrombotic thrombocytopenic
4
thrombocytopenic purpura
4
purpura associated
4
associated adamts13
4
deficiency unlabelled
4

Similar Publications

Introduction: Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially life-threatening complication whose association with COVID-19 is controversial. Understanding this connection is essential due to its significant impact on patient outcomes, and timely diagnosis and intervention are critical in managing this condition effectively.

Areas Covered: This paper presents a case of TTP triggered by COVID-19 infection in a 48-year-old female.

View Article and Find Full Text PDF

Microangiopathic Hemolytic Anemia: A Rare Complication of Acute Pancreatitis.

Korean J Gastroenterol

January 2025

Section of Haematology, Department of Pathology and Laboratory Medicine, Aga Khan University, Karachi, Pakistan.

Microangiopathic hemolytic anemia (MAHA) is a rare subtype of hemolytic anemia characterized by elevated hemolytic markers and red blood cell destruction. Though uncommon, MAHA can occur as a complication of acute pancreatitis because of the associated inflammatory response. Patients with MAHA secondary to pancreatitis show favorable outcomes when treated with plasma exchange.

View Article and Find Full Text PDF

Congenital thrombotic thrombocytopenic purpura (cTTP) is a thrombotic microangiopathy (TMA) characterized by severe hereditary ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motifs 13) deficiency caused by mutations. This rare autosomal recessive genetic disorder is often misdiagnosed as immune thrombocytopenia (ITP) or hemolytic uremic syndrome (HUS). Here, we report a 21-year-old male cTTP patient with a compound heterozygous mutation.

View Article and Find Full Text PDF

Thrombotic thrombocytopenic purpura (TTP) is characterized by thrombotic microangiopathy resulting from decreased activation of the von Willebrand factor-cleaving protease (ADAMTS13). TTP can cause organ damage and is often fatal if the appropriate treatment is not started immediately. Although primary immune TTP is the most common form of TTP, secondary immune etiologies, including complications from immune checkpoint inhibitors (ICIs), have also been reported.

View Article and Find Full Text PDF

Purpose Of Review: This review aims to examine recent advances in the understanding of injury-induced endotheliopathy and therapeutics to mitigate its development in critically injured patients.

Recent Findings: Clinical studies have clearly demonstrated that syndecan-1 ectodomains can be found in circulation after various types of trauma and injury and correlates with worse outcomes. As the mechanisms of endotheliopathy are better understood, pathologic hyperadhesive forms of von Willebrand factor, along with a relative deficiency of its cleaving enzyme, a disintegrin and metalloprotease with thrombospondin type I motifs, member 13 (ADAMTS13), have emerged as additional biomarkers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!